Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 15, 2016
Reporting Period: Second Quarter ended June 30, 2016
This filing serves as a current report to announce the Company's financial results for the quarter ended June 30, 2016, and to provide a clinical update. The detailed financial data is contained within the press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover document (Form 8-K) and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific data to compare current period results against prior comparable periods. It only confirms the issuance of results for the quarter ended June 30, 2016.
Guidance, Outlook, and Management Commentary
Management Commentary: The press release referenced in this filing includes a "Clinical Update" alongside financial results.
Guidance and Risks: The filing text does not contain specific forward-looking guidance, risk factors, or details on contingencies. These items are presumed to be in the attached Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2016 revenue, net loss, and cash burn rates.
- Verify the details of the "Clinical Update" mentioned in the press release title.
- Check the Company's cash position and runway as disclosed in the full press release.
- Confirm any changes in clinical trial timelines or regulatory milestones.